- Home
- LUCD vs FBIO Comparison
LUCD vs FBIO Comparison
Compare LUCD & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | FBIO |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 113.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCD | FBIO |
|---|---|---|
| Price | $1.17 | $3.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.94 | ★ $16.50 |
| AVG Volume (30 Days) | 588.8K | ★ 1.2M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,399,000.00 | ★ $62,303,000.00 |
| Revenue This Year | $7.69 | $29.71 |
| Revenue Next Year | $155.47 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.01 | N/A |
| 52 Week Low | $0.81 | $1.33 |
| 52 Week High | $1.80 | $4.53 |
Technical Indicators
Market Signals| Indicator | LUCD | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 47.17 |
| Support Level | $1.12 | $3.25 |
| Resistance Level | $1.24 | $3.79 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 22.72 | 18.75 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.